Hemophilia Market (By Type: Hemophilia A, Hemophilia B, Hemophilia C; By Treatment: On-demand, Prophylaxis; By Therapy: Replacement Therapy, Gene Therapy) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format: PDF | Status: Published | Pages : 160

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
       1.1.1. Definition of Hemophilia
       1.1.2. Market Segmentation
       1.1.3. List of Abbreviations
1.2. Summary
       1.2.1. Market Snapshot
       1.2.2. Hemophilia Market By Type
                 1.2.2.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Type (2015-2026)
                 1.2.2.2. Global Hemophilia Market Revenue Share By Type in 2017
                 1.2.2.3. Hemophilia A
                 1.2.2.4. Hemophilia B
                 1.2.2.5. Hemophilia C
                 1.2.2.6. Others
       1.2.3. Hemophilia Market By Treatment
                 1.2.3.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Treatment (2015-2026)
                 1.2.3.2. On-demand
                 1.2.3.3. Prophylaxis
                 1.2.3.4. Others
       1.2.4. Hemophilia Market By Therapy
                 1.2.4.1. Global Hemophilia Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
                 1.2.4.2. Replacement Therapy
                 1.2.4.3. Gene Therapy
                 1.2.4.4. Others
       1.2.5. Hemophilia Market by Geography
                 1.2.5.1. Global Hemophilia Market Revenue and Growth Rate Comparison by Geography (2015-2026)
                 1.2.5.2. North America Hemophilia Market Revenue and Growth Rate (2015-2026)
                 1.2.5.3. Europe Hemophilia Market Revenue and Growth Rate (2015-2026)
                 1.2.5.4. Asia-Pacific Hemophilia Market Revenue and Growth Rate (2015-2026)
                 1.2.5.5. Latin America Hemophilia Market Revenue and Growth Rate (2015-2026)
                 1.2.5.6. Middle East and Africa (MEA) Hemophilia Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
       2.4.1. Bargaining Power of Suppliers
       2.4.2. Bargaining Power of Buyers
       2.4.3. Threat of Substitute
       2.4.4. Threat of New Entrants
       2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
       2.6.1. Raw Material and Suppliers
       2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
       2.8.1. Player Positioning Analysis
       2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemophilia Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemophilia Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Hemophilia Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemophilia Major Manufacturers in 2017

CHAPTER 4. HEMOPHILIA MARKET BY TYPE

4.1. Global Hemophilia Revenue By Type
4.2. Hemophilia A
       4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Hemophilia B
       4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Hemophilia C
       4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Other
       4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEMOPHILIA MARKET BY TREATMENT

5.1. Global Hemophilia Revenue By Treatment
5.2. On-demand
       5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Prophylaxis
       5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
       5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEMOPHILIA MARKET BY THERAPY

6.1. Global Hemophilia Revenue By Therapy
6.2. Replacement Therapy
       6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Gene Therapy
       6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
       6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOPHILIA MARKET BY COUNTRY

7.1. North America Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
       7.3.1. U.S. Hemophilia Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       7.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       7.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.4. Canada
       7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       7.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       7.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.5. Mexico
       7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       7.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       7.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEMOPHILIA MARKET BY COUNTRY

8.1. Europe Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
       8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       8.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       8.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.4. Germany
       8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       8.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       8.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.5. France
       8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       8.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       8.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.6. Spain
       8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       8.6.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       8.6.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.7. Rest of Europe
       8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       8.7.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       8.7.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOPHILIA MARKET BY COUNTRY

9.1. Asia-Pacific Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
       9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       9.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       9.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.4. Japan
       9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       9.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       9.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.5. India
       9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       9.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       9.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.6. Australia
       9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       9.6.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       9.6.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.7. South Korea
       9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       9.7.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       9.7.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
       9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
       9.8.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
       9.8.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOPHILIA MARKET BY COUNTRY

10.1. Latin America Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
        10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        10.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        10.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.4. Argentina
        10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        10.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        10.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.5. Rest of Latin America
        10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        10.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        10.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOPHILIA MARKET BY COUNTRY

11.1. Middle East Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
        11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        11.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        11.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.4. UAE
        11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        11.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        11.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.5. Rest of Middle East
        11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        11.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        11.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA HEMOPHILIA MARKET BY COUNTRY

12.1. Africa Hemophilia Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Hemophilia Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
        12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        12.3.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        12.3.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.4. Egypt
        12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        12.4.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        12.4.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.5. Rest of Africa
        12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
        12.5.2. Market Revenue and Forecast By Treatment, 2015 - 2026 ($Million)
        12.5.3. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Baxalta
        13.1.1. Company Snapshot
        13.1.2. Overview
        13.1.3. Financial Overview
        13.1.4. Type Portfolio
        13.1.5. Key Developments
        13.1.6. Strategies
13.2. CSL Behring
        13.2.1. Company Snapshot
        13.2.2. Overview
        13.2.3. Financial Overview
        13.2.4. Type Portfolio
        13.2.5. Key Developments
        13.2.6. Strategies
13.3. Pfizer, Inc.
        13.3.1. Company Snapshot
        13.3.2. Overview
        13.3.3. Financial Overview
        13.3.4. Type Portfolio
        13.3.5. Key Developments
        13.3.6. Strategies
13.4. Bayer Healthcare
        13.4.1. Company Snapshot
        13.4.2. Overview
        13.4.3. Financial Overview
        13.4.4. Type Portfolio
        13.4.5. Key Developments
        13.4.6. Strategies
13.5. BioMarin Pharmaceutical, Inc.
        13.5.1. Company Snapshot
        13.5.2. Overview
        13.5.3. Financial Overview
        13.5.4. Type Portfolio
        13.5.5. Key Developments
        13.5.6. Strategies
13.6. Biogen
        13.6.1. Company Snapshot
        13.6.2. Overview
        13.6.3. Financial Overview
        13.6.4. Type Portfolio
        13.6.5. Key Developments
        13.6.6. Strategies
13.7. Chugai Pharmaceutical Co.
        13.7.1. Company Snapshot
        13.7.2. Overview
        13.7.3. Financial Overview
        13.7.4. Type Portfolio
        13.7.5. Key Developments
        13.7.6. Strategies
13.8. Novo Nordisk
        13.8.1. Company Snapshot
        13.8.2. Overview
        13.8.3. Financial Overview
        13.8.4. Type Portfolio
        13.8.5. Key Developments
        13.8.6. Strategies
13.9. Shire Plc.
        13.9.1. Company Snapshot
        13.9.2. Overview
        13.9.3. Financial Overview
        13.9.4. Type Portfolio
        13.9.5. Key Developments
        13.9.6. Strategies
13.10. Others
          13.10.1. Company Snapshot
          13.10.2. Overview
          13.10.3. Financial Overview
          13.10.4. Type Portfolio
          13.10.5. Key Developments
          13.10.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
         14.1.1. Initial Data Search
         14.1.2. Secondary Research
         14.1.3. Primary Research
14.2. Assumptions and Scope


Cart Summary